Prospective evaluation of oral mucositis in acute leukemia patients receiving chemotherapy
- 286 Downloads
Knowledge of oral mucositis (OM) in patients with acute leukemia (AL) and chemotherapy (CT) has remained limited. Thus, a prospective, longitudinal study was undertaken to characterize clinical features, associated risk factors, and behavior of OM in a cohort of AL patients starting CT.
Prospective and longitudinal study. A cohort of patients, older than 15 years of age with AL, scheduled to receive CT, was followed from March 2006 to October 2007. At baseline and three times per week, for 21 days, patients had an oral examination performed using the Oral Mucositis Assessment Scale (OMAS); also, oral pain and difficulty to swallow were recorded using a visual analog scale. Weekly, salivary flow measurements (Schirmer’s test modified version) were done.
A cohort of 29 AL patients was followed for a median time of 21 (range, 14–53) days; 12 (41.4%) developed OM, with a mean OMAS score of 0.181 (SD ± 0.56) and a mean peak OMAS score of 1.8 (SD ± 0.56). The OM onset mean time was 9.8 (range, 2–20, SD ± 6.09) days, with a mean duration of 7 (range, 3–14, SD ± 4.15) days. OM was significantly correlated with salivary flow [rs = 0.420 (P = 0.0051)], oral pain [rs = 0.47 (P < 0.0001)], ability to swallow [rs = 0.36 (P = 0.0001)], and type of food intake [rs = 0.38 (P < 0.0001)].
OM is a frequent and early side effect of CT closely correlated with oral pain, difficulty to swallow, and impairment in food intake.
KeywordsOral mucositis Chemotherapy Acute leukemia Salivary flow
- 7.Blijlevens N, Schwenkglenks M, Bacon P et al (2008) European blood and marrow transplantation mucositis advisory group. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 26:1519–1525CrossRefPubMedGoogle Scholar
- 22.STROBE Group. STROBE Statement. Checklist of essential items, version 3. http://www.strobe.statement.org/PDF/STROBE-Checklist-Version 3.pdf. Accessed January 30, 2009.
- 24.Arteaga-Ortiz L, Buitrón-Santiago N, Rosas-López A et al (2008) Acute limphoblastic leukemia: experience in adults patients treated with hyperCVAD and 0195 Protocol, at the Institute Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003–2007. Rev Invest Clin 60(6):459–469PubMedGoogle Scholar
- 29.Matthews DE, Farewell VT (1985) Using and understanding medical statistics. Karger, BaselGoogle Scholar
- 36.Elad S, Ackerstein A, Bitan M et al (2006) A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplant 37:757–762CrossRefPubMedGoogle Scholar
- 47.Keefe DM, Schubert MM, Elting LS et al (2007) Mucositis study section of the multinational association of supportive care in cancer and the international society for oral oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRefPubMedGoogle Scholar